News stories about Jounce Therapeutics (NASDAQ:JNCE) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Jounce Therapeutics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.3032031008251 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
JNCE has been the topic of several recent research reports. Robert W. Baird reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research report on Monday, September 18th. Zacks Investment Research lowered shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.67.
Jounce Therapeutics (NASDAQ:JNCE) traded up $0.49 during trading hours on Friday, hitting $15.04. 150,068 shares of the stock were exchanged, compared to its average volume of 134,611.
Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. The firm had revenue of $20.29 million during the quarter, compared to the consensus estimate of $19.94 million. During the same period in the prior year, the business earned ($7.23) EPS. equities analysts anticipate that Jounce Therapeutics will post -0.73 earnings per share for the current fiscal year.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
What are top analysts saying about Jounce Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jounce Therapeutics Inc. and related companies.